ALK and lung cancer: In treatment-naïve lung cancer, oncogenic driver mutations, such as epidermal growth factor receptor (EGFR), Kirsten rat sarcoma virus (KRAS), BRAF, anaplastic lymphoma kinase (ALK), and ROS1, typically occur as trunk mutations with little intratumoral heterogeneity [31].